Summary of Key Points Core Viewpoint - On November 10, several A-share listed companies disclosed their shareholding changes, with some announcing share buybacks while others reported share reductions by major shareholders [1]. Group 1: Share Buybacks - Hangcai Co. proposed to use 50 million to 100 million yuan of surplus funds for share repurchase [2]. - Sunong Bank executives plan to increase their holdings by no less than 1.8 million yuan in A-shares within six months [2]. - Jiangsu Cable's controlling shareholder received loan support for increasing A-share holdings [2]. Group 2: Share Reductions - A total of 25 A-share listed companies announced share reductions, including: - Aojing Medical plans to reduce no more than 0.19% of its shares by directors and executives [2]. - Maipu Medical's shareholder Guoshou Chengda intends to reduce no more than 1% of its shares [2]. - Shoulv Hotel's Ctrip Shanghai reduced 25.206 million shares on November 10 [2]. - Mingchen Health's controlling shareholder plans to reduce no more than 3% of the total share capital [2]. - Meiri Interactive's shareholder "I Got a Push" intends to reduce no more than 1% of its shares [2]. - Qicai Chemical's shareholder Beijing Fengyan plans to reduce no more than 0.98% of its shares [2]. - Other companies with planned reductions include Zhongheng Design, Xin Kaipu, Lianying Laser, Hongxin Electronics, and others, with reductions ranging from 0.07% to 5% [2].

Core Points - The company announced the nomination of candidates for its third board of directors, including both non-independent and independent directors [2] Group 1: Board of Directors Nominations - The board of directors has approved the nomination of Huang Wanlan, Qiu Zhiye, Song Tianxi, Tian Guofeng, and Liu Yang as non-independent director candidates [2] - The board has also approved the nomination of Su Jian, Li Xiaoming, and Zhao Lingyun as independent director candidates, with Su Jian being a professional accountant [2]

Core Viewpoint - The company, Aojing Medical (688613.SH), announced plans for share reduction by key executives due to personal funding needs, which may impact investor sentiment and stock performance [1] Summary by Relevant Sections Share Reduction Plans - The company's general manager, Mr. Qiu Zhiye, plans to reduce his holdings by up to 95,000 shares, representing no more than 0.07% of the total share capital [1] - The financial officer, Ms. Wang Ling, intends to reduce her holdings by up to 70,312 shares, accounting for no more than 0.05% of the total share capital [1] - Vice general managers, Mr. Song Tianxi and Mr. Tian Guofeng, plan to reduce their holdings by up to 50,000 shares (0.04%) and 37,500 shares (0.03%) respectively [1] Implementation Timeline - The reduction plans will be executed within three months starting from 15 trading days after the announcement [1] - The total number of shares reduced through centralized bidding will not exceed 1% of the company's total shares over any continuous 90-day period [1] Adjustments and Pricing - Any changes in share capital due to stock dividends, capital reserve transfers, or other share changes will lead to corresponding adjustments in the planned reduction amounts [1] - The reduction price will be determined based on market prices and the method of transaction [1]

证券代码：688613 证券简称：奥精医疗 公告编号：2025-061 奥精医疗科技股份有限公司 董事及高级管理人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 董事及高级管理人员持股的基本情况 截至本公告披露日，奥精医疗科技股份有限公司（以下简称"公司 "）本次 拟减持的董事及高级管理人员持股情况如下： 公司董事、总经理仇志烨先生持有公司股份 380000 股，占公司总股本的比 例为 0.28%；公司财务负责人、高级管理人员王玲女士持有公司股份 281250 股， 占公司总股本的比例为 0.21%；公司董事、副总经理宋天喜先生持有公司股份 200000 股，占公司总股本的比例为 0.15%；公司董事、副总经理田国峰先生持 有公司股份 150000 股，占公司总股本的比例为 0.11%；上述股份来源为股权激 励取得，均为无限售条件流通股。 减持计划的主要内容 因自身资金需求，公司董事、总经理仇志烨先生，公司财务负责人、高级管 理人员王玲女士，公司董事、副总经理宋天喜先生，公司 ...

Core Viewpoint - The company, Aojing Medical (688613.SH), announced plans for share reduction by key executives due to personal funding needs, which may impact investor sentiment and stock performance [1] Summary by Relevant Sections Share Reduction Plans - The company's general manager, Mr. Qiu Zhiye, plans to reduce his holdings by up to 95,000 shares, representing no more than 0.07% of the total share capital [1] - The financial officer, Ms. Wang Ling, intends to reduce her holdings by up to 70,312 shares, accounting for no more than 0.05% of the total share capital [1] - Vice general managers, Mr. Song Tianxi and Mr. Tian Guofeng, plan to reduce their holdings by up to 50,000 shares (0.04%) and 37,500 shares (0.03%), respectively [1] Implementation Timeline - The reduction plans will be executed within three months starting from 15 trading days after the announcement [1] - The total number of shares reduced through centralized bidding will not exceed 1% of the company's total shares over any continuous 90-day period [1] Adjustments and Pricing - Any changes in share capital due to stock dividends, capital reserve transfers, or other corporate actions will lead to corresponding adjustments in the planned reduction amounts [1] - The reduction price will be determined based on market conditions and the method of transaction [1]

Core Viewpoint - Aozheng Medical (688613.SH) announced that several key executives plan to reduce their shareholdings due to personal funding needs [1] Group 1: Shareholding Reduction Details - CEO Qiu Zhiye plans to reduce his holdings by up to 95,000 shares, representing no more than 0.07% of the company's total share capital [1] - Financial officer Wang Ling intends to reduce her holdings by up to 70,312 shares, accounting for no more than 0.05% of the total share capital [1] - Vice President Song Tianxi aims to reduce his holdings by up to 50,000 shares, which is no more than 0.04% of the total share capital [1] - Vice President Tian Guofeng plans to reduce his holdings by up to 37,500 shares, representing no more than 0.03% of the total share capital [1]

Core Viewpoint - The announcement from Aojing Medical (688613.SH) indicates that several key executives plan to reduce their shareholdings in the company due to personal funding needs [1] Summary by Relevant Categories Shareholding Reduction - CEO Qiu Zhiye plans to reduce his holdings by no more than 95,000 shares, representing up to 0.07% of the total share capital [1] - Financial officer Wang Ling intends to reduce her holdings by no more than 70,312 shares, accounting for up to 0.05% of the total share capital [1] - Vice President Song Tianxi aims to reduce his holdings by no more than 50,000 shares, which is up to 0.04% of the total share capital [1] - Vice President Tian Guofeng plans to reduce his holdings by no more than 37,500 shares, representing up to 0.03% of the total share capital [1]

Core Viewpoint - The company, AoJing Medical (688613), announced plans for share reductions by several key executives, indicating potential changes in insider ownership and market sentiment [1] Group 1: Share Reduction Plans - The company's general manager, Qiu Zhiye, plans to reduce holdings by up to 95,000 shares [1] - The financial officer and senior manager, Wang Ling, intends to reduce holdings by up to 70,300 shares [1] - The company's vice general managers, Song Tianxi and Tian Guofeng, plan to reduce holdings by up to 50,000 shares and 37,500 shares, respectively [1] - The total shares to be reduced by these executives amount to no more than 0.19% of the company's total share capital [1]

Core Viewpoint - The announcement from AoJing Medical indicates that several executives plan to reduce their shareholdings due to personal financial needs, which may impact investor sentiment and stock performance [1] Summary by Relevant Sections Executive Shareholding Reduction - CEO Qiu Zhiye intends to reduce his holdings by no more than 95,000 shares, accounting for up to 0.07% of total shares [1] - CFO Wang Ling plans to sell up to 70,312 shares, representing no more than 0.05% [1] - Vice President Song Tianxi aims to decrease his stake by up to 50,000 shares, which is about 0.04% [1] - Vice President Tian Guofeng will reduce his holdings by no more than 37,500 shares, equivalent to approximately 0.03% [1] Timeline for Share Reduction - The reduction period is set from December 3, 2025, to March 3, 2026 [1] Source of Shares - All shares to be sold are derived from equity incentives received by the executives [1]

奥精医疗科技股份有限公司 董事和高级管理人员持股 二〇二五年十一月 及持股变化管理办法 奥精医疗科技股份有限公司 董事和高级管理人员持股及持股变化管理办法 奥精医疗科技股份有限公司 董事和高级管理人员持股 及持股变化管理办法 第一章 总则 第一条 为加强对奥精医疗科技股份有限公司（以下简称"公司"或"本公 司"）董事和高级管理人员所持本公司股份及其变动的管理，进一步明确办理程 序，根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共 和国证券法》（以下简称"《证券法》"）《上市公司董事和高级管理人员所持 本公司股份及其变动管理规则》《上海证券交易所科创板股票上市规则》等法 律、法规、规范性文件及《奥精医疗科技股份有限公司章程》（以下简称"《公 司章程》"）的规定，并结合公司具体情况，制定本办法。 第二条 本办法适用于公司董事和高级管理人员所持本公司股份及其变动 的管理。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其名下的 和利用他人账户持有的所有本公司股份。公司董事和高级管理人员从事融资融 券交易的，还包括记载在其信用账户内的本公司股份。对同时开立多个证券账 户、客户信用证券账户的 ...